<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-four children with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated beginning May 1976 with a regimen alternating high doses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> in induction and consolidation; only high doses of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were used in the maintenance phase </plain></SENT>
<SENT sid="1" pm="."><plain>Throughout therapy, which was planned for 54 weeks, intrathecal chemoprophylaxis using <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, and <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> was coordinated with the high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> infusion therapy to provide <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> chemoprophylaxis that maintained therapeutic <z:chebi fb="0" ids="44185">methotrexate</z:chebi> spinal fluid levels (greater than 10(-6) mol/L) for approximately 60 hours </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-two (92%) of the 24 children attained complete remission; two (8.3%) patients attained only partial remission, failing therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Two children died of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> while in complete remission; two children relapsed on therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Actual survival is 75%; the median follow-up time is 38+ months (range, 1 1/2+ to 84+ months) </plain></SENT>
<SENT sid="5" pm="."><plain>Relapses correlated with Murphy disease stage as follows: stage I--0/3, stage II--2/7, stage III--2/10, and stage IV--0/2 </plain></SENT>
<SENT sid="6" pm="."><plain>Serious side effects and toxicities of chemotherapy occurred in ten patients (metabolic disturbances after rapid <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lysis, two; infectious and/or febrile episodes following <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> therapy, three; <z:chebi fb="0" ids="44185">methotrexate</z:chebi> side effects, four; and complications of intrathecal therapy, one) </plain></SENT>
<SENT sid="7" pm="."><plain>Results of this therapy are similar to those of the best regimens that have been reported </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment has been adapted for use in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> by the Pediatric <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group; the responsiveness of other B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of childhood to this treatment is also being determined </plain></SENT>
</text></document>